Mackenzie Financial Corp Has $1.42 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Key Points

• Mackenzie Financial Corp significantly increased its stake in Amneal Pharmaceuticals by 1,281.5%, acquiring 156,609 shares to own a total of 168,830 shares valued at approximately $1.4 million.
• Amneal Pharmaceuticals reported earnings of $0.19 per share, exceeding analysts' expectations, but noted a negative net margin of 0.46% and a return on equity of -188.26%.
• Analysts have an average rating of "Buy" for Amneal Pharmaceuticals, with a consensus price target of $11.60, following various rating adjustments from multiple research firms.

Mackenzie Financial Corp grew its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 1,281.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 168,830 shares of the company's stock after acquiring an additional 156,609 shares during the period. Mackenzie Financial Corp owned 0.05% of Amneal Pharmaceuticals worth $1,415,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in AMRX. GAMMA Investing LLC raised its position in shares of Amneal Pharmaceuticals by 5,975.0% in the first quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock valued at $26,000 after buying an additional 3,107 shares in the last quarter. Amalgamated Bank raised its holdings in Amneal Pharmaceuticals by 33.0% in the 1st quarter. Amalgamated Bank now owns 5,511 shares of the company's stock valued at $46,000 after acquiring an additional 1,367 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at $52,000. Straightline Group LLC bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at $92,000. Finally, Xponance Inc. grew its holdings in shares of Amneal Pharmaceuticals by 16.1% during the 1st quarter. Xponance Inc. now owns 13,183 shares of the company's stock worth $110,000 after purchasing an additional 1,828 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on AMRX. The Goldman Sachs Group assumed coverage on shares of Amneal Pharmaceuticals in a research report on Friday, June 6th. They set a "buy" rating and a $12.00 price objective for the company. Wall Street Zen downgraded shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, May 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $11.60.

Amneal Pharmaceuticals Trading Up 3.7%

Amneal Pharmaceuticals stock traded up $0.31 during midday trading on Friday, reaching $8.52. The company's stock had a trading volume of 944,642 shares, compared to its average volume of 1,670,859. The stock has a market cap of $2.67 billion, a PE ratio of 851.35 and a beta of 1.11. Amneal Pharmaceuticals, Inc. has a 52 week low of $6.68 and a 52 week high of $9.48. The business has a 50-day moving average price of $7.99 and a 200-day moving average price of $7.96.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. As a group, research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.